EarlySense, Ltd., developer of "smart systems" for monitoring changes in a patient's clinical condition, announced that it has received FDA clearance for its ES-16 system, which monitors heart and respiratory rates in children and adults. The technology developed by EarlySense uses a proprietary contact-free sensor, which does not require physical connection to the body of the patient. The ES-16 system eliminates patient discomfort and enables the cost-effective monitoring of patients in settings such as homes, hospitals, and other clinic settings, such as long-term care facilities. The system has been under evaluation at several clinical settings in patients who suffer from chronic diseases, such as asthma, chronic obstructive pulmonary disease, and chronic heart failure, as well as at acute care facilities in critical care patients and patients hospitalized for various medical and postoperative conditions. EarlySense intends to start selling its new product, to be named EverOn, in 2008 after several beta sites evaluations in Israel and the United States. EarlySense, Ltd. was founded in 2004. The company is headquartered in Ramat-Gan, Israel. For additional information, please visit http://www.earlysense.com.